We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current BCRX market cap is 1.61B. The company's latest EPS is USD -0.4253 and P/E is -18.03.
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 93.4M | 92.76M | 109.33M | 117.09M | 131.53M |
| Operating Income | -42.67M | -14.49M | 8.76M | 7.69M | -4.51M |
| Net Income | -61.73M | -35.38M | -12.67M | -14.03M | -26.8M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 17.81M | 157.17M | 270.83M | 331.41M | 450.71M |
| Operating Income | -174.76M | -177.72M | -148.44M | -103.71M | -2.54M |
| Net Income | -182.81M | -184.06M | -247.12M | -226.54M | -88.88M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 516.96M | 467.89M | 472.42M | 491.25M | 490.42M |
| Total Liabilities | 972.49M | 944.06M | 948.03M | 959.82M | 966.35M |
| Total Equity | -455.53M | -476.17M | -475.61M | -468.56M | -475.93M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 334.72M | 588.15M | 550M | 516.96M | 490.42M |
| Total Liabilities | 353.98M | 695.14M | 844.6M | 972.49M | 966.35M |
| Total Equity | -19.26M | -106.99M | -294.6M | -455.53M | -475.93M |
| Quarter End | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -95.14M | -53.68M | -55.05M | -46.81M | -52.02M |
| Investing | -131.5M | 28.76M | 26.31M | 34.8M | 52.59M |
| Financing | 32.49M | -1.05M | -3.01M | -1.74M | -5.76M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -137.22M | -142.16M | -161.85M | -95.14M | -52.02M |
| Investing | -6.86M | 15.8M | -128.24M | -131.5M | 52.59M |
| Financing | 302.7M | 359.67M | 88.03M | 32.49M | -5.76M |
| Market Cap | 1.61B |
| Price to Earnings Ratio | -18.03 |
| Price to Sales Ratio | 3.56 |
| Price to Cash Ratio | 15.31 |
| Price to Book Ratio | -3.37 |
| Dividend Yield | - |
| Shares Outstanding | 208.96M |
| Average Volume (1 week) | 4.99M |
| Average Volume (1 Month) | 4.2M |
| 52 Week Change | 46.48% |
| 52 Week High | 9.50 |
| 52 Week Low | 4.03 |
| Spread (Intraday) | 0.27 (3.47%) |
| Company Name | BioCryst Pharmaceuticals Inc |
| Address |
2711 centerville road wilmington, delaware 19808 |
| Website | https://www.biocryst.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
